NCT04209855: An ongoing trial by ImmunoGen, Inc.
This trial is ongoing. It must report results 5 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT04209855 |
|---|---|
| Title | MIRASOL: A Randomized, Open-label, Phase 3 Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Dec. 31, 2019 |
| Completion date | Sept. 30, 2023 |
| Required reporting date | Sept. 29, 2024, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Feb. 9, 2024 |
| Days late | None |